You are here

Publications

Found 381 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is G  [Clear All Filters]
2026
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Vinette V, Castro A, Kim H, Trujillo C, Xie M, Gengenbacher M, Ioerger TR, Ehrt S.  2026.  Interstitial and recruited macrophages prevent tuberculosis relapse by limiting immune evasion.. EMBO Mol Med.
Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al..  2026.  A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.